Sanofi SA (SAN.FR) received approval for its follow-on mealtime insulin injection Admelog by the U.S. Food and Drug Administration, the company said late Monday.
Admelog will be available in the U.S. in vial form and as a prefilled disposable insulin pen, Sanofi said.
Continue Reading Below
The treatment is a follow-on insulin lispro--a fast-acting insulin--for diabetics who need to manage blood sugar levels at meal times, the company said.
Admelog received authorization from the European Commission in July 2017 to be marketed as a biosimilar under the name Insulin lispro Sanofi.
Write to Max Bernhard at Max.Bernhard@dowjones.com; @mxbernhard
(END) Dow Jones Newswires
December 12, 2017 01:31 ET (06:31 GMT)